As is evident from previous work with ABL kinase inhibitors for chronic myeloid leukemia and antivirals for HIV and hepatitis (Shah et al., 2004; Glickman and Sawyers, 2012), understanding mechanisms of drug resistance is a crucial first step in developing strategies to prevent or overcome it. This evidence concerns the gene ABL1 and hepatitis A virus infection.